Deciphera

Why Shares of Deciphera Pharmaceuticals Rose This Week
Why Shares of Deciphera Pharmaceuticals Rose This Week
Motley Fool
Deciphera
earnings
Qinlock
GIST
Flag link:
ESMO 2022 movers – KRAS backfires
ESMO 2022 movers – KRAS backfires
EP Vantage
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Flag link:
3 Biotech Stocks With Huge Catalysts Incoming
3 Biotech Stocks With Huge Catalysts Incoming
Motley Fool
BeyondSpring
Allakos
Deciphera
plinabulin
lirentelimab
Qinlock
Flag link:
FDA approval tracker: several early decisions in May
FDA approval tracker: several early decisions in May
EP Vantage
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Fierce Pharma
Blueprint Medicines
Deciphera
FDA
GIST
Ayvakit
Qinlock
Flag link:
Deciphera files for approval of cancer drug ahead of schedule
Deciphera files for approval of cancer drug ahead of schedule
Fierce Biotech
Deciphera
ripretinib
gastrointestinal stromal tumors
FDA
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Deciphera soars as phase 3 cancer data tee up FDA filing
Deciphera soars as phase 3 cancer data tee up FDA filing
Fierce Biotech
Deciphera
clinical trials
ripretinib
gastrointestinal stromal tumors
Flag link:
Deciphera expands cancer trial after seeing early data
Deciphera expands cancer trial after seeing early data
Fierce Biotech
Deciphera
DCC-3014
TGCTs
cancer
clinical trials
Flag link:
ASCO spotlight presaged two more biotech IPOs angling for $215M
ASCO spotlight presaged two more biotech IPOs angling for $215M
Endpoints
ASCO
IPOs
biotech
Deciphera
DCC-2618
Nucana
Acelarin
Flag link: